FDA warned Todos Medical over selling Tollovid as an unapproved COVID-19 drug and misbranded product.
What happened
FDA reviewed the company’s websites, social media, and Amazon storefront on June 23, 2022. It found Tollovid offered for sale in the U.S. with claims that it can prevent, treat, or cure COVID-19. FDA said the product is an unapproved new drug and misbranded.
What FDA found
Tollovid is an unapproved new drug because it is sold for a COVID-19 use without FDA approval.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)Tollovid is a misbranded drug under the FD&C Act.
section 502 of the FD&C Act, 21 U.S.C. § 352The product cannot be introduced or delivered into interstate commerce.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
What FDA wants
FDA tells Todos Medical to stop selling unapproved COVID-19 products immediately and to email the steps it has taken within 48 hours, including how it will prevent repeat violations and supporting documents. If it cannot complete action within 48 hours, it must state why and give a timeline.
Who should pay attention
- consumers who bought COVID-19 products online
- retailers and online marketplaces listing supplements
- supplement companies making disease-treatment claims
This is a summary. Read the original letter on fda.gov.